Universal Health Services (UHS) trades at a decade-low valuation despite strong EPS growth and robust capital returns. UHS guides for 2026 revenue, EBITDA, and EPS growth of 7%, 5%, and 9% at the midpoint, outpacing peer HCA. Key risks include ACA subsidy expirations and Medicaid reimbursement cuts, but downside appears priced in at current levels.